Remyelination in humans due to a retinoid-X receptor agonist is age-dependent
- PMID: 35587315
- PMCID: PMC9268872
- DOI: 10.1002/acn3.51595
Remyelination in humans due to a retinoid-X receptor agonist is age-dependent
Abstract
Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid-X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only. Addressing this age-related decline in human remyelination capacity will be an important step in the development of remyelinating therapies that work across the lifespan.
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Conflict of interest statement
CEM, TM, AWM, AJC, and NGC report no conflict of interest. JWLB reports personal fees from Biogen for real‐world evidence consultation, outside the submitted work. DTC is a consultant for Biogen and Hoffmann‐La Roche. In the last 3 years he has received research funding from Hoffmann‐La Roche, the International Progressive MS Alliance, the MS Society, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, and speaker's honorarium from Novartis. He co‐supervises a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which is supported by Merck. RJMF reports consulting fees from Frequency Therapeutics, Rewind Therapeutics and Biogen.
Figures


Comment in
-
Ageing reduces potential for remyelination in multiple sclerosis.Nat Rev Neurol. 2022 Jul;18(7):381. doi: 10.1038/s41582-022-00680-3. Nat Rev Neurol. 2022. PMID: 35641684 No abstract available.
Similar articles
-
The MS Remyelinating Drug Bexarotene (an RXR Agonist) Promotes Induction of Human Tregs and Suppresses Th17 Differentiation In Vitro.Front Immunol. 2021 Aug 10;12:712241. doi: 10.3389/fimmu.2021.712241. eCollection 2021. Front Immunol. 2021. PMID: 34447379 Free PMC article.
-
News in multiple sclerosis: Remyelination as a therapeutic target.Med Clin (Barc). 2017 Apr 21;148(8):377-380. doi: 10.1016/j.medcli.2016.10.021. Epub 2016 Dec 4. Med Clin (Barc). 2017. PMID: 27923464 Review. English, Spanish. No abstract available.
-
Using the Anterior Visual System to Assess Neuroprotection and Remyelination in Multiple Sclerosis Trials.Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):49. doi: 10.1007/s11910-018-0858-y. Curr Neurol Neurosci Rep. 2018. PMID: 29923130 Review.
-
Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.JAMA Neurol. 2020 Feb 1;77(2):234-244. doi: 10.1001/jamaneurol.2019.3283. JAMA Neurol. 2020. PMID: 31566686 Free PMC article.
-
Effects of disease-modifying therapies on remyelination in multiple sclerosis; evaluation via visual evoked potential test.Mult Scler Relat Disord. 2024 Nov;91:105850. doi: 10.1016/j.msard.2024.105850. Epub 2024 Aug 30. Mult Scler Relat Disord. 2024. PMID: 39232395
Cited by
-
Multiple Sclerosis and Aging: The Dynamics of Demyelination and Remyelination.ASN Neuro. 2022 Jan-Dec;14:17590914221118502. doi: 10.1177/17590914221118502. ASN Neuro. 2022. PMID: 35938615 Free PMC article. Review.
-
Inflammation in multiple sclerosis: consequences for remyelination and disease progression.Nat Rev Neurol. 2023 May;19(5):305-320. doi: 10.1038/s41582-023-00801-6. Epub 2023 Apr 14. Nat Rev Neurol. 2023. PMID: 37059811 Review.
-
Clemastine and metformin extend the window of NMDA receptor surface expression in ageing oligodendrocyte precursor cells.Sci Rep. 2024 Feb 19;14(1):4091. doi: 10.1038/s41598-024-53615-x. Sci Rep. 2024. PMID: 38374232 Free PMC article.
-
Vitamin A5: Evidence, Definitions, Gaps, and Future Directions.Nutrients. 2025 Jul 14;17(14):2317. doi: 10.3390/nu17142317. Nutrients. 2025. PMID: 40732942 Free PMC article. Review.
-
Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis.Int J Mol Sci. 2023 Mar 28;24(7):6373. doi: 10.3390/ijms24076373. Int J Mol Sci. 2023. PMID: 37047344 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical